Sign In
Buy GTBP
$0.439
-0.0279 (-5.97%)
At Close: Jun 03, 2026
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
08:00am, Monday, 01'st Jun 2026
Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing devel
The $13 Million Company Teaching the Immune System to Hunt Cancer
09:00am, Friday, 29'th May 2026
/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
02:22pm, Monday, 18'th May 2026
/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
GT Biopharma Reports First Quarter 2026 Financial Results
08:00am, Friday, 15'th May 2026
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to expr
GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalat
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
08:16am, Thursday, 14'th May 2026
GT Biopharma Inc. (NASDAQ:GTBP) on Thursday dosed the first patient on a Phase 1 dose-escalation basket trial evaluating GTB-5550, its B7-H3-targeted NK cell engager for solid tumors expressing B7-H3.
Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)
01:59am, Thursday, 02'nd Apr 2026
Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies bas
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know
01:00pm, Monday, 16'th Mar 2026
GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:55am, Thursday, 12'th Mar 2026
GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean
GT Biopharma to Participate in the 38th Annual Roth Conference
07:00am, Wednesday, 11'th Mar 2026
SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics
GT Biopharma Reports Full Year 2025 Financial Results
07:00am, Monday, 02'nd Mar 2026
Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
07:30am, Tuesday, 17'th Feb 2026
SAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeuti
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31,
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extend cas
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
08:01am, Thursday, 15'th Jan 2026
GT Biopharma Inc. (NASDAQ: GTBP) on Thursday said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in December 2025 for GTB-5550 TriKE for soli
